For erectile dysfunction, the pills work — and they're the evidence-backed first step

For most men with erectile dysfunction, the oral pills work — and both the trial evidence and the guidelines make them, alongside attention to the underlying health problem, the sensible first thing to try [s1][s2]. The class is the phosphodiesterase type 5 inhibitors: sildenafil (Viagra), tadalafil (Cialis), vardenafil and newer agents such as avanafil. The best evidence says all of them beat placebo, they differ only modestly from one another, and they are broadly safe [s1].

What the trials show

The most comprehensive comparison pooled 118 randomised trials covering 31,195 men in a network meta-analysis [s1]. Every PDE5 inhibitor improved erectile function compared with placebo [s1]. The differences between drugs were real but small: tadalafil ranked as the most effective agent, followed by vardenafil, while avanafil was less effective than both on a global measure of whether erections improved (relative risk 0.61 versus tadalafil and 0.63 versus vardenafil) [s1]. On the standard erectile-function questionnaire, tadalafil outscored vardenafil by a mean of 1.49 points [s1]. On safety there was no major difference between the drugs; all were generally well tolerated [s1].

Two practical points sit underneath those averages. First, the tablets do not create an erection on their own — they require sexual stimulation to work, which is why men who believe they have "failed" a pill have often not used it correctly. Second, the drugs differ in timing more than in kind: tadalafil's long half-life allows a low daily dose or a window of a day or more, while the others are taken as needed before sex. Matching the drug to how a man wants to use it matters as much as the ranking. It is also worth trying a drug properly before judging it a failure: the trials dosed men adequately and, for some agents, over several attempts, which is not how a first prescription is always used at home.

What the guideline recommends

The American Urological Association's evidence-based guideline is built around shared decision-making [s2]. Its central instruction is that all men should be informed of every treatment that is not contraindicated — regardless of how invasive or irreversible — as a potential first-line option, so the choice reflects the man's own priorities rather than a fixed ladder [s2]. In practice the conversation starts with the reversible, low-burden options: lifestyle change and a PDE5 inhibitor for most men, with vacuum devices, injections into the penis, urethral suppositories and, ultimately, surgical implants as further-line choices for men who do not respond or cannot take the tablets [s2].

The signal not to miss

Erectile dysfunction is often the first outward sign of a vascular problem, because the small arteries of the penis narrow before the larger coronary ones do. New-onset erectile trouble in a middle-aged man is a reason to check blood pressure, glucose and lipids, not just to reach for a prescription — the link between erection problems and heart risk is one of the more useful early warnings in men's medicine. Treating the symptom with a pill while ignoring the diabetes or hypertension behind it misses the more important diagnosis.

There are also interactions that make the pills genuinely dangerous for some men: PDE5 inhibitors must never be combined with nitrate heart medicines, because the two together can cause a catastrophic drop in blood pressure. That contraindication, and a handful of others, is exactly why "informed of all options" in the guideline is not a formality [s2].

What it means for a reader

The plain answer to what actually helps erectile dysfunction is that the oral PDE5 inhibitors have the strongest and largest evidence base — 118 trials, tens of thousands of men, a consistent benefit over placebo — and they are where most men should reasonably start once their overall health is checked [s1]. The differences between the branded tablets are modest enough that convenience, cost and how a man wants to use the drug matter more than the leaderboard [s1]. When the pills fail or cannot be used, the guideline's menu of devices, injections and implants offers well-established alternatives, and the right frame throughout is a shared decision rather than a default [s2]. What should never be skipped is the check for the vascular disease that erectile dysfunction so often announces first.